Free NewsletterPro Login

Free Live Investors Workshop

Seats limited

Tue, Sep 29.

The dollar is losing value.

Here’s how investors can still profit.

Hosted By

Jaspreet Singh

Founder, Briefs Finance

X
Free Live Investor Workshop

Alcon chief warns U.S. price-linking push could keep some drugs off European shelves

Published Sep 14, 2026
Share:
Summary:
  • Alcon CEO David Endicott said tying U.S. drug prices to levels abroad could mean some medicines never launch in Europe.
  • At the end of August, the Swiss eye-care company was part of a group of nine pharma and biotech firms that signed pricing agreements with the U.S., aimed at keeping its medicines available to American patients.
  • Endicott told Bloomberg Television on Monday that the U.S. plans to negotiate based on prices outside the country while Alcon works to balance broad access with shareholder responsibility.

What Endicott Said

In a Monday interview with Bloomberg Television, David Endicott cautioned that the White House's plan to align U.S. drug costs with those in other countries may lead some companies to skip European launches rather than accept lower prices that could affect the large U.S. market. As he put it, "different prices outside the US are going to be negotiated by the US." He also said, "We're trying to make sure we maintain access as broadly as we can, but obviously being responsible to shareholders."

Alcon's Position

Headquartered in Switzerland and specializing in eye care - from surgical equipment to contact lenses and medicines - Alcon was part of a cohort of nine pharma and biotech companies that struck drug-pricing deals with U.S. officials at the end of August. The goal is to keep Alcon's medicines accessible to U.S. patients as the administration works to tie American prices to those in other developed markets. Endicott noted, "Every market is going to develop its own reimbursement system, its own negotiation, and we do that around the world," and added, "We'll continue to push around the world to figure out what that implication means as we negotiate prices as we always have."

Policy changes can affect access to products, so investors safeguard capital and patience. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.

Why It Matters For Your Portfolio

Many new therapies come cheaper outside the U.S., and Washington wants American prices to track those benchmarks. If some drugmakers decide it is better for their U.S. business to avoid lower price anchors in Europe, launch strategies could shift and access timelines might change for patients in different regions.

Preserving spending power means staying informed and building resilient long term strategies. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.

Disclosure

Recent News

1 2 3 78

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.
0 Shares
Share via
Copy link